{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP04854",
    "Peptide Name": "RIK-10+ (LL-37mini2; Synthetic AMPs, LL-37 derived, Arg-rich, XXA, UCLL1c; BBMm)",
    "Source": "amino acid truncation, amino acid substitution, human cathelicidin analog, animal-derived, natural derivative",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "RWKRFLRNWV",
    "Sequence Length": 10,
    "UniProt Entry": "Ref",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram+",
      "Gram-",
      "Anti-MRSA",
      "Antibiofilm"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Helix",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 5,
    "Boman Index": 4.03,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "50%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "Sequence analysis: APD analysis reveals that this sequence is similar (70%) toRIK-10R: 30%, W: 20%. GRAVY: -1.19, mol Wt: 1460.749; mol formula: C70H108N22O12; mol ex coeff: 11100.Activity: active against S. aureus USA300 MRSA (MIC 16 uM), S-epidermidis 1457 (MIC >32 uM), P. aeruginosa E411-17 (MIC 4 ug/ml), E. coli E423-17 (MIC 4 uM), and A. baumannii B28-16 (MIC 8 uM).Biofilms: Inhibited biofilm formation:bacteria:S. aureus; inhibited biofilm formation:bacteria:P. aeruginosa; disrupted preformed biofilm:bacteria:S. aureus; disrupted preformed biofilm:bacteria:P. aeruginosa;In vitro toxicity: human RBC: not hemo.lytic till 100 uM (HC50 >400 uM). Not toxic to human keratinocyte HaCaT cells (LC50 100 uM), human hepatoma HepG2 cells (LC50 100 uM), and human lung carcinoma A549 cells (LC50 >100 uM) at least at the MIC.MOA:bacteria:S. aureus USA300: membrane permeation. Also, MOA:bacteria:P.aeruginosa.Structure:  RIK-10+ is helical bound to DPC micelles.Animal model:mouse: wound healing model:S. aureus: ~2 logs CFU reduction after treatment once at 10 mg/kg.",
    "Author": "Mechesso AF, Zhang W, Su Y, Xie J, Wang G. 2024",
    "Reference": "Probiotics Antimicrob Proteins. 2024 Oct 8. doi: 10.1007/s12602-024-10376-3.PubMed",
    "Title": "Segment-Based Peptide Design Reveals the Importance of N-Terminal High Cationicity for Antimicrobial Activity Against Gram-Negative Pathogens."
  },
  "3D Structure": []
}